Edwards Lifesciences has lifted its 2025 profit outlook to between 9%-10%, up from 8%-10%, amid strong Q2 2025 performance in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) business segments.
The California-based company now expects an adjusted profit near the upper end of its previously forecast range of $2.40 to $2.50 per share for 2025, corresponding to profits between $5.9bn and $6.1bn for the year.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Shares in Edwards were up by more than 5% in pre-trading on 25 July following the result’s announcement on 24 July.
Edwards financials revealed total sales of $1.53bn in Q2 2025, marking an 11.9% rise on Q2 2024 sales of $1.39bn.
Edwards TAVR segment grew to $1.1bn in Q2 2025, an 8.9% increase on Q2 2024. The company said the increase was chiefly driven by the continued adoption of its SAPIEN technology, with clinical conversations around its EARLY TAVR trial (NCT03042104) data bringing a renewed focus to streamlining the management of patients with severe aortic stenosis (AS).
The trial results demonstrated that early intervention for severe AS before symptoms develop improved patient outcomes and reduced the economic and resource burden on healthcare systems.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEdwards stated that the market share adjustments in Europe after the November 2020 discontinuation of Boston Scientific’s Lotus Edge TAVR system contributed modestly to its overall sales in the segment.
Edwards has revised its 2025 TAVR outlook to between 6% to 7%, up from the previous range of 5% to 7%.
GlobalData medical analyst David Beauchamp commented: “It isn’t shocking to see Edwards doing well within the TAVR space – Boston Scientific stopped manufacturing of their ACURATE Aortic Valve Systems earlier this year, leaving a small space in the market for other major players, such as Edwards and Medtronic, to fill.
“Edwards remains the dominant player within the aortic valve market.”
According to GlobalData analysis, the global TAVR market is growing at a compound annual growth rate (CAGR) of 8.1% and is projected to reach a valuation of around $14.95bn by 2033, up from $6.86bn in 2024.
In Q2 2025, Edwards reported sales of $134.5m in its TMTT segment, a 61.9% rise compared to Q2 2024. The company attributed the growth to the ongoing adoption of its PASCAL technology and steady progress of its EVOQUE system, which received CE marking in Europe in October 2023 and US Food and Drug Administration (FDA) approval in February 2024.
Beauchamp commented: “The TMTT sector, which includes Edwards’ mitral valve repair and tricuspid valve replacement technologies, continues to grow as those devices continue to be adopted and utilized for more procedures every year.
“The continued adoption of transcatheter technologies for heart valve repair and replacement procedures are likely to continue to drive this high growth.”
Elsewhere across the business, the surgical segment generated sales of $267m, reflecting a 7.7% rise on Q2 2024.
Edwards CEO Bernard Zovighian commented: “We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook.”
